



Department of Medical Education
Himalayan Institute of Medical Sciences
Swami Rama Himalayan University
Swami Ram Nagar, P.O. Jolly Grant, Dehradun- 248016



**Chairman & Officer
In-charge**

Lt. Gen. Dr. Daljit
Singh. (Retd.)

Coordinator

Dr. Juhi Kalra

Members

Dr. Ashok K. Deorari
Dr. V. D. Chauhan
Dr. Sanjoy Das
Dr. Anuradha Kustum
Dr. Renu Dhasmana
Dr. Alpa Gupta
Dr. Deepa Singh
Dr. Bamali Kakati
Dr. Hemant Kr. Nautiyal
Dr. Atul Agarwal
Dr. Aarti Kotwal
Dr. Kiran Bhat
Dr. Saurabh Kohli
Dr. Sanobar Wasim
Dr. Lovneesh Kumar
Dr. Ramkumar S.
Dr. Neha Sharma
Dr. Anita Sharma
Dr. Shaili Vyas

HIMS/DME/2025/161

Date: 04.07.2025

Clinical Grand Round

Date : 05.07.2025
Day : Saturday

Time: 08:30 AM – 09:30 AM
Venue: Adi-Kailash Auditorium
(Near - Emergency Building)

First 10-minute Topic / Title: "Snippets from the Subconscious"

Presenter: Dr. Rajeev Mohan Kaushik, Professor
Dept. General Medicine

The book gives an idea about this science and narrates true stories of hypnosis.

Topic: Immunotherapy Beyond Expectations: Long-Term Control of Advanced Lung Adenocarcinoma.

Abstract:

Background:

Stage IV lung adenocarcinoma is typically associated with poor prognosis. However, the advent of immune checkpoint inhibitors targeting the PD-1/PD-L1 axis has significantly changed the therapeutic landscape, particularly in patients with high PD-L1 expression.

Case Presentation:

We report the case of a 54-year-old male diagnosed with stage IV lung adenocarcinoma, exhibiting $\geq 50\%$ PD-L1 expression on tumor cells. The patient was initiated on first-line chemo-immunotherapy with a PD-1 inhibitor ([e.g., pembrolizumab]), leading to a remarkable clinical response. Over 3.5 years of follow-up, the patient has remained progression-free with excellent performance status and manageable immune-related adverse events.

Discussion:

This case highlights the potential for durable responses and long-term survival in advanced non-small cell lung cancer (NSCLC) with high PD-L1 expression when treated with immune checkpoint inhibitors. Factors such as biomarker-driven therapy selection, close monitoring, and prompt management of side effects were essential to the positive outcome.

Conclusion:

High PD-L1 expression without any driver mutation in advanced lung adenocarcinoma can predict favorable response to immunotherapy. This case contributes to the growing body of evidence supporting long-term survival with immune checkpoint blockade in select patients.

Programme for Clinical Grand Round:

Presentation	Speaker	Time
Introduction	Prof S K Verma	05 minutes
Case Presentation	Dr Cherry Bansal	08 minutes
Biomarkers	Dr Akanksha Aggarwal	08 minutes
Overview of Immunotherapy	Prof S K Verma/Dr Ankit Batra	20 minutes
Q & A	Prof S K Verma/Dr Ankit Batra	10 minutes

All Faculty & Post Graduate Residents are required to attend the Clinical Grand Round.

Department: Medical Oncology

Convenor
NMC Regional Centre
Himalayan Institute of Medical Sciences...
Swami Rama Himalayan University
Jolly Grant, Dehradun-248016
Coordinator
D.M.E.

Email Id: dme.hims@srhu.edu.in